← Eichor
Study identifier: NCT06367530 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Trilateral Retinoblastoma: Incidence and Outcomes

Condition: Trilateral Retinoblastoma · Retinoblastoma  ·  Sponsor: Amsterdam UMC, location VUmc

PhaseN/A
Planned participants4351
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Patients with heritable retinoblastoma are at risk to develop an intracranial brain tumor, which is often fatal. The investigators intend to look at the incidence and survival of trilateral retinoblastoma (which is a brain tumor that can either be located in the pineal gland or elsewhere in the brain) in retinoblastoma patients globally. All retinoblastoma patients from participating centers will be included. The investigators hypothesize that the apparent incidence of trilateral retinoblastoma (especially the usually later diagnosed pineal trilateral retinoblastoma) in low-income countries will be lower because of low chances of surviving the ocular tumors at about 50% and also because of possible under-diagnosis. Therefore, as retinoblastoma care improves in low-income countries the incidence of (pineal) trilateral retinoblastoma might go up. Knowledge about incidence and survival can help improve health practices in parts of the world where this might be needed. Therefore this global study firstly aims 1) to evaluate survival after trilateral retinoblastoma and factors influencing survival and 2) to evaluate incidence of trilateral retinoblastoma by country income level. The study will run from 2024 through 2027.

This description comes directly from the study's public registry record.

Talk to the study team

Marcus C de Jong, MD PhD  ·  +31(0)20-4443047  ·  mc.dejong@amsterdamumc.nl

Pim de Graaf, MD PhD  ·  +31(0)20-4443047  ·  p.degraaf@amsterdamumc.nl

Always discuss trial participation with your own doctor first.

Locations (1)

Amsterdam UMCAmsterdam, North Holland, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06367530